The University of Chicago Header Logo

Connection

Mark J. Ratain to Carcinoma, Non-Small-Cell Lung

This is a "connection" page, showing publications Mark J. Ratain has written about Carcinoma, Non-Small-Cell Lung.
  1. Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues? Eur J Cancer. 2023 11; 194:113349.
    View in: PubMed
    Score: 0.499
  2. In Silico Re-Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposure-Response Simulation. J Clin Pharmacol. 2023 06; 63(6):672-680.
    View in: PubMed
    Score: 0.478
  3. Lorlatinib Exposed: A Far From Optimal Dose. Clin Pharmacol Ther. 2022 06; 111(6):1195-1196.
    View in: PubMed
    Score: 0.451
  4. Influence of N-acetyltransferase 2 gene polymorphisms on the in vitro metabolism of the epidermal growth factor receptor inhibitor rociletinib. Br J Clin Pharmacol. 2021 11; 87(11):4313-4322.
    View in: PubMed
    Score: 0.423
  5. Models of excellence: improving oncology drug development. Clin Pharmacol Ther. 2012 Nov; 92(5):548-50.
    View in: PubMed
    Score: 0.235
  6. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst. 2007 Oct 03; 99(19):1455-61.
    View in: PubMed
    Score: 0.165
  7. Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies. Clin Cancer Res. 1999 Jun; 5(6):1325-30.
    View in: PubMed
    Score: 0.093
  8. Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions. Cancer Res. 2011 Apr 01; 71(7):2423-7.
    View in: PubMed
    Score: 0.052
  9. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010 Oct 28; 363(18):1693-703.
    View in: PubMed
    Score: 0.051
  10. Bar the windows but open the door to randomization. J Clin Oncol. 2010 Jul 01; 28(19):3104-6.
    View in: PubMed
    Score: 0.050
  11. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol. 2008 Mar 01; 26(7):1119-27.
    View in: PubMed
    Score: 0.042
  12. Irinogenetics: what is the right star? J Clin Oncol. 2006 May 20; 24(15):2221-4.
    View in: PubMed
    Score: 0.037
  13. Phase II oncology trials: let's be positive. Clin Cancer Res. 2005 Aug 15; 11(16):5661-2.
    View in: PubMed
    Score: 0.036
  14. EGFR pharmacogenomics: the story continues to mutate and evolve. Am J Pharmacogenomics. 2005; 5(2):137-9.
    View in: PubMed
    Score: 0.034
  15. Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer. 2003 May 15; 97(10):2480-6.
    View in: PubMed
    Score: 0.030
  16. Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19. JAMA Oncol. 2020 11 01; 6(11):1694-1695.
    View in: PubMed
    Score: 0.026
  17. A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer. Ann Oncol. 1998 Oct; 9(10):1085-90.
    View in: PubMed
    Score: 0.022
  18. A phase I study of intermittent infusion cladribine in patients with solid tumors. Cancer. 1994 Jul 01; 74(1):168-73.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.